SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Photronics, Inc. engages in the provision of photomasks, which are quartz or glass plates containing microscopic images of electronic circuits for use in the fabrication of integrated circuits and flat-panel displays. The company was founded by Constantine S. Macricostas in 1969 and is headquartered in Brookfield, CT.

Photronics, Inc.

Photronics is gaining significant community attention as a deeply undervalued 'pure play' in the photomask market, with investors betting that its critical role in AI chip manufacturing will drive a major re-rating. While the stock has faced downward pressure following recent earnings and guidance misses, the bullish sentiment centers on its strong balance sheet, lack of debt, and its potential as an essential supplier for the expanding AI and semiconductor landscape.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors weigh an upcoming earnings report and management updates against ongoing concerns about the company's post-TDAPA reimbursement outlook. The community is actively debating the potential for major contract wins with dialysis providers while maintaining a polarized sentiment over management's communication and the stock's long-term growth trajectory.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is currently under pressure as investors weigh concerns about slowing broadband subscriber growth and competition from alternative providers like Starlink against the company's attractive dividend and discounted valuation. Community sentiment is deeply divided, with some investors accumulating shares as a long-term value play, while others remain skeptical, citing poor customer service and the transition of legacy email accounts as catalysts for ongoing churn.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending as TD Cowen named the coffee chain a top small-midcap pick for 2026, citing strong fundamentals, aggressive store expansion, and an underappreciated food rollout. Community discussions remain highly active as investors weigh the company's growth-driven valuation against its continued popularity and foot traffic performance.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is attracting significant community attention as it navigates market volatility, with sentiment split between holders anticipating a major rebound and skeptics raising concerns about long-term sustainability. Discussions are heavily fueled by traders debating the broader meme coin supercycle, with many investors actively comparing its performance to other major meme assets.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render (RENDER) is trending as investors focus on its critical role in DePIN and decentralized AI infrastructure, with the community actively debating whether current price levels offer a strong entry point for long-term accumulation. Discussions are heavily driven by the sector's real-world adoption narrative and the token's strategic position in powering AI and GPU compute demand.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus Energy is trending as investors react to a recent letter of intent to supply HALEU fuel to Oklo, positioning the company as a critical domestic bottleneck solution for the surging AI energy demand. While the stock has faced recent volatility, the community remains intensely focused on the long-term potential of the domestic nuclear fuel supply chain and the company's strategic moats in an era of constrained grid capacity.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently trending as investors weigh strong oncology trial data against dilution concerns and a recent market sell-off, with community sentiment split between conviction in the drug's blockbuster potential and frustration over trial transparency. The active discussion is heavily focused on significant insider buying from leadership, which many view as a bullish signal for long-term valuation ahead of major clinical milestones.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley is trending as the firm secures lead underwriting roles for major upcoming IPOs, such as SpaceX, while institutional investors rotate into the bank's stock amid a broader rally in the financial sector. Simultaneously, market participants are actively debating the bank's long-term growth prospects as it expands its footprint in crypto ETFs and data center financing.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending following an FDA advisory committee's unanimous endorsement of its experimental mRNA flu vaccine, a development investors view as a pivotal validation of the company's platform and future commercial growth. The community remains heavily divided, with bulls highlighting the company's expanding oncology and infectious disease pipeline, while bears continue to focus on concerns regarding historical product performance and the ongoing debate surrounding public trust in mRNA technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?

CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.

Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio?

Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.

Top Analyst Reports for Costco, Lam Research & KLA

Costco, Lam Research and KLA headline Zacks' top analyst reports, with AI demand, digital investments and expansion plans driving focus.

Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.

Cytokinetics (NASDAQ:CYTK) Posts Quarterly Earnings Results

Cytokinetics (NASDAQ:CYTK - Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.67) EPS for the quarter, hitting analysts' consensus estimates of ($1.67). The business had revenue of $19.36 million for the quarter, compared to analyst...

Cytokinetics Q1 Earnings Call Highlights

Cytokinetics (NASDAQ:CYTK) highlighted the first full quarter as a commercial-stage company during its first-quarter 2026 earnings call, pointing to early U.S. demand for its newly launched...

Cytokinetics (NASDAQ:CYTK) EVP Sells $270,795.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $77.37, for a total value of $270,795.00. Following the sale, the executive vice president...

Cytokinetics Shares Phase 3 ACACIA-HCM Win: Aficamten Hits Dual Endpoints in nHCM Trial

Cytokinetics (NASDAQ:CYTK) reported positive top-line results from ACACIA-HCM, a pivotal Phase 3 trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy...

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -0.20% and +173.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$78.78
Prev Close	$78.11
Open	$79.41
Dividend Yield	0.00%
50-Day Moving Average	$70.93
Beta	0.90
Avg. Volume	3.62M
PE Ratio	-11.51

52-Week High	$80.20
52-Week Low	$31.99
Market Capitalization	$9.8B
EPS (Annual)	-$6.54
Price to Book	-11.84
Revenue Per Employee	$130,815.75

CYTKCytokinetics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYTK News